Clinical Development Scientist

ARTBIO; Cambridge; In loco; GBP 75.000 - 110.000; Tempo pieno

Descrizione del lavoro

ARTBIO is seeking a Clinical Development Scientist to act as the day-to-day clinical lead for an Radioligand Therapy program. You will own the study protocol, chair the study team, and drive timelines while turning emerging clinical data into pivotal decisions that advance the asset.

The role reports to the VP, Clinical Development and collaborates with functional heads and SMEs to ensure program integrity and timely execution across activities.

Competenze

• Designing and authoring clinical trial protocols.
• Chairs the study team and drives the timeline.
• Translates clinical data into decision points for asset advancement.

Mansioni

• Act as day-to-day clinical lead for an RLT development program.
• Coordinate cross-functional collaboration with PMs, statisticians, and medical monitors.
• Ensure timely progress from study initiation to data-driven decisions.

Conoscenze

Clinical development

Protocol design

Project management

Leadership

Descrizione del lavoro

Summary

We are seeking a Clinical Development Scientist to act as the day-to-day clinical lead for one of ARTBIO’s Radioligand Therapy (RLT) development programs, combining scientific ownership of the study with hands-on project management of its execution. Reporting to the VP, Clinical Development and working closely with functional heads and subject matter experts, you will be the person who holds the program together: designing and authoring the protocol, chairing the study team, driving the timeline, and turning emerging clinical data into the decisions that advance the asset.

About Us

Channeling Energy. Changing Lives. ARTBIO redefines cancer care by discovering and developing a new class of Alpha Radioligand Therapies (ARTs), powered by unique Pb-212 isotope technology and seamless supply. Our team works tirelessly to bring therapies that matter to patients who need them.

The unique ARTBIO approach selects the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for the highest efficacy and safety. The company’s AlphaDirect technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs, with lead program AB001 currently in first-in-human trials. The company is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital.

Cancer is relentless. So are we. We are driven by a desire to do better for cancer patients, lowering the burden of toleration and safety while at the same time raising the bar on clinical efficacy and duration. As an emerging, global biotech with locations in Boston, Basel, London, and Oslo, we take advantage of diverse scientific depth and insights, which makes ARTBIO a unique place to work.

EEO Statement

ARTBIO is proud to be an equal opportunity workplace and is an affirmative action employer. We are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status. If you have a disability or special need that requires accommodation, please let us know.

ARTBIO does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between ARTBIO and the agency. ARTBIO will not pay any fees related to unsolicited resumes.